Drugs / Albuferon
Albuferon
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00656006 | Nov 2005 → Apr 2007 | chronic hepatitis C virus infection | Human Genome Sciences Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00115908 | May 2005 → May 2007 | chronic hepatitis C virus infection | Human Genome Sciences Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00097435 | Oct 2004 → Aug 2007 | hepatitis C virus infection | Human Genome Sciences Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Albuferon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00115908 ↗ |
| Known as | alb-IFN | “The efficacy and safety of albinterferon alfa-2b (alb-IFN), a novel recombinant protein consisting of interferon alfa-2b genetically fused to human albumin, was evaluated in a...” PMID 18666223 ↗ Aug 2008 |
| Known as | albinterferon alfa-2b | “Albinterferon alfa-2b is a novel, long-acting, fusion polypeptide that is dosed q2wk or q4wk.” PMID 19447518 ↗ Mar 2009 |
| Known as | HGS 1008 | “A Randomized, Multi-Center, Open-Label Study To Evaluate The Efficacy And Safety Of Albuferon (HGS 1008, Recombinant Human Albumin-Interferon Alfa Fusion Protein) In...” NCT00656006 ↗ |
| Modality | Protein / enzyme biologic | “Albuferon (Recombinant Human Albumin-Interferon Alfa Fusion Protein)” NCT00097435 ↗ |
| Route | Subcutaneous | “1,200 microg once every four weeks (q4wk), administered subcutaneously” PMID 18666223 ↗ Aug 2008 |